---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-025156"
form_type: "8-K"
ticker: "ACUT"
cik: "0001850767"
company_name: "Accustem Sciences Inc."
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:35:41.053566+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AccuStem submits Medicare coverage application for MSC lung cancer test; enters Novitas review

## Summary
- Submitted local coverage determination to Novitas Solutions for MSC test reimbursement.
- Novitas confirmed application complete and valid; now in review queue for JL region (DC, DE, MD, NJ, PA).
- MSC test analyzes 24 circulating microRNAs in plasma to classify lung nodule risk.
- If approved, could reduce unnecessary biopsies for benign nodules and prioritize high-risk patients.

## SEC filing metadata
- accession: 0001493152-25-025156
- form_type: 8-K
- ticker: ACUT
- cik: 0001850767
- company_name: Accustem Sciences Inc.
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850767/000149315225025156/0001493152-25-025156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850767/000149315225025156/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-025156
- JSON: https://secwatch.observer/filing/0001493152-25-025156.json
- Plain text: https://secwatch.observer/filing/0001493152-25-025156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.